<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1004221930
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ULTIVA 5MG VIAL(LYOPHILIZED)
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        REMIFENTANIL HYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Controlled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        369.35
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="GLAXOSMITHKLINE (GSK)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            GLAXOSMITHKLINE (GSK)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Aspen Pharma Trading Limited
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N01AH06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>1-What Ultiva is and what it is used for</strong><br />Ultiva contains a medicine called remifentanil. This belongs to a group of medicines known as opioids.</p><p>Ultiva is used together with other medicines called anaesthetics</p><ul><li>to help put you to sleep before an operation</li><li>to keep you asleep and stop you feeling pain during an operation</li><li>to make you feel sleepy and stop you feeling pain while you receive treatment in an Intensive Care Unit.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>2-What you need to know before you are given Ultiva</strong></p><p><strong>Do not have Ultiva if:</strong></p><ul><li>you are allergic (hypersensitive) to remifentanil or any of the other ingredients of Ultiva (listed in section 6)</li><li>you are allergic (hypersensitive) to any other pain-relieving medicines which are similar to fentanyl and which are related to the class of medicines known as opioids.</li></ul><p>If you are not sure if any of the above apply to you, talk to your doctor, pharmacist or nurse before you are given Ultiva.</p><p><strong>Warnings and precautions</strong></p><p>Check with your doctor or pharmacist before you are given Ultiva if:</p><ul><li>you are allergic (hypersensitive) to any other opioid medicines, such as morphine or codeine</li><li>you are over 65 years of age</li><li>you are dehydrated or have lost a lot of blood</li><li>you have been feeling weak or unwell</li><li>if you are overweight</li></ul><p>If you are not sure if any of the above apply to you, talk to your doctor, pharmacist or nurse before you are given Ultiva.</p><p><strong>Other medicines and Ultiva</strong></p><p>Please tell your doctor or pharmacist if you are taking or have recently taken or might take other medicines, including medicines obtained without a prescription. This includes herbal medicines. This is because Ultiva can work with other medicines to cause side effects.<br />In particular tell your doctor or pharmacist if you are taking:</p><ul><li>&nbsp;medicines for your heart or blood pressure, such as beta-blockers (these include atenolol, metoprolol, carvedilol, propanolol and bisoprolol) or calcium channel blockers (these include amlodipine, diltiazem and nifedipine).</li></ul><p>Concomitant use of Ultiva and sedative medicines such as benzodiazepines or related drugs increases the risk of drowsiness, difficulties in breathing (respiratory depression), coma and may be life-threatening. Because of this, concomitant use should only be considered when other treatment options are not possible.</p><p>However if your doctor does prescribe Ultiva together with sedative medicines the dose and duration of concomitant treatment should be limited by your doctor.</p><p>Please tell your doctor about all sedative medicines you are taking, and follow your doctor&rsquo;s dose recommendation closely. It could be helpful to inform friends or relatives to be aware of the signs and symptoms stated above. Contact your doctor when experiencing such symptoms.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before you are given this medicine.</p><p><strong>Driving and using machines</strong></p><p>If you are only staying in hospital for the day, your doctor will tell you how long to wait before leaving the hospital or driving a car. It can be dangerous to drive too soon after having an operation.</p><p>The medicine can affect your ability to drive as it may make you sleepy or dizzy.</p><ul><li>Do not drive while taking this medicine until you know how it affects you.</li><li>It is an offence to drive if this medicine affects your ability to drive.</li><li>However, you would not be committing an offence if:</li></ul><p>o The medicine has been prescribed to treat a medical or dental problem and<br />o You have taken it according to the instructions given by the prescriber or in the information provided with the medicine and<br />o It was not affecting your ability to drive safely</p><p>Talk to your doctor or pharmacist if you are not sure whether it is safe for you to drive while taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>3-How Ultiva is given</strong></p><p><strong>How your injection is given</strong></p><p>You will never be expected to give yourself this medicine. It will always be given to you by a person who is qualified to do so.<br />Ultiva can be given:</p><ul><li>as a single injection into your vein</li><li>as a continuous infusion into your vein. This is where the drug is slowly given to you over a longer period of time.</li></ul><p>The way you are given the drug and the dose you receive will depend on:</p><ul><li>your weight</li><li>the operation you have</li><li>how much pain you will be in</li><li>how sleepy the medical staff want you to be in the Intensive Care Unit.</li></ul><p>The dose varies from one patient to another.</p><p><strong>If you are given too much</strong></p><p>The effects of Ultiva are carefully monitored throughout your operation and in intensive care, and appropriate action will be taken promptly if you receive too much.</p><p><strong>After your operation</strong></p><p>Tell your doctor or nurse if you are in pain. If you are in pain after your procedure, they will be able to give you other painkillers.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>4-Possible side effects</strong></p><p>Like all medicines, Ultiva can cause side effects, although not everybody gets them. The following side effects may happen with this medicine.</p><p>Some people can be allergic to Ultiva.<strong> You must tell your doctor or nurse immediately if you have:</strong></p><p><strong>Rare</strong> (may affect up to 1 in 1,000 people)</p><ul><li>&nbsp;sudden wheeziness and chest pain or chest tightness</li><li>&nbsp;swelling of your eyelids, face, lips, mouth or tongue</li><li>a lumpy skin rash or &lsquo;hives&rsquo; anywhere on the body</li><li>collapse.</li></ul><p>Tell your doctor <strong>as soon as possible</strong> if you notice any of the following:</p><p><strong>Very common</strong> (may affect more than 1 in 10 people)</p><ul><li>muscle stiffness</li><li>low blood pressure</li><li>feeling sick or being sick</li></ul><p><strong>Common</strong> (may affect up to 1 in 10 people)</p><ul><li>&nbsp;slow heartbeat</li><li>&nbsp;shallow breathing or temporarily stop breathing</li><li>&nbsp;itching</li></ul><p><strong>Uncommon</strong> (may affect up to 1 in 100 people)</p><ul><li>&nbsp;problems breathing (hypoxia)</li><li>constipation</li></ul><p><strong>Rare</strong> (may affect up to 1 in 1,000 people)</p><ul><li>&nbsp;allergic reactions</li><li>heart stops beating</li></ul><p><strong>Not known </strong>(frequency cannot be estimated from the available data)</p><ul><li>physical need for Ultiva (drug dependency) or the need for increasing doses over time to get the same effect (drug tolerance)</li><li>&nbsp;fits (seizures)</li><li>&nbsp;a type of irregular heartbeat (atrioventricular block)</li></ul><p><strong>Other side effects that can happen when you wake up after having an anaesthetic include:</strong><br /><strong>Common</strong> (may affect up to 1 in 10 people)</p><ul><li>shivering</li><li>&nbsp;increases in blood pressure</li></ul><p><strong>Uncommon </strong>(may affect up to 1 in 100 people)</p><ul><li>aches</li></ul><p><strong>Rare</strong> (may affect up to 1 in 1,000 people)</p><ul><li>feeling very calm or drowsy (sedation)</li></ul><p><strong>Other side effects which occurred particularly upon abrupt cessation of Ultiva after prolonged administration of more than 3 days</strong></p><ul><li>heart beating faster (tachycardia)</li><li>high blood pressure (hypertension)</li><li>&nbsp;restlessness (agitation)</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>5-How to store Ultiva</strong></p><ul><li>Keep this medicine out of the sight and reach of children.</li><li>&nbsp;Do not use Ultiva after the expiry date which is stated on the vial and carton after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</li><li>Do not store above 25C.</li><li>When Ultiva is made up it should be used straight away. Any unused solution should not be disposed of via wastewater or household waste. Your doctor or nurse will throw away any medicine that is no longer required. This will help protect the environment.</li><li>Store in the original package with this leaflet.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a.What Ultiva contains</strong><br />The active substance is remifentanil hydrochloride.<br />The other ingredients are glycine and hydrochloric acid (for pH adjustment).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                b.What Ultiva looks like and contents of the pack
Ultiva for injection is a sterile, non-pyrogenic, preservative-free, white to off-white, lyophilised powder and is available in the following strengths:
- 1 mg Ultiva for injection, in 3 ml glass vials
- 2 mg Ultiva for injection, in 5 ml glass vials
- 5 mg Ultiva for injection, in 10 ml glass vials
The powder will be mixed with an appropriate fluid before being injected. When mixed to form a solution, Ultiva is clear and colourless.
Each strength of Ultiva is supplied in cartons containing 5 vials.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>c.Marketing Authorisation Holder and Manufacturer</strong></p><p><strong>Marketing Authorisation Holder:</strong></p><p>Aspen Pharma Trading Limited, 3016 Lake Drive, Citywest Business Campus, Dublin 24, Ireland</p><p><strong>Manufacturer:</strong></p><p>GlaxoSmithKline Manufacturing S.p.A., San Polo di Torrile, Parma, Italy</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                d. This leaflet was last approved in {August/2019}; version number {002}
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p><strong>1-ما هو ألتيفا وما هي دواعي استخدامه</strong>&nbsp;<br />يحتوي ألتيفا على دواء يُسمى ريميفينتانيل . وهو ينتمي إلى مجموعة من الأدوية يطلق عليها الأفيونات.</p><p>يستخدم ألتيفا إلى جانب أدوية أخرى تُسمى أدوية التخدير</p><ul><li>&nbsp;لتساعد المرضى على النوم قبل الخضوع للعمليات</li><li>&nbsp;لإبقاء المريض نائماً وتخدير الشعور بالألم خلال الخضوع للعمليات</li><li>&nbsp;لإشعار المرضى بالنعاس وتخدير الشعور بالألم أثناء تلقي العلاج في وحدة العناية المركزة.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>2-ما الذي تحتاج لمعرفته قبل تلقي ألتيفا&nbsp;</strong><br />يجب ألا يتم إعطاؤك ألتيفا في الحالات التالية:</p><ul><li>&nbsp;إذا كنت مصاباً بحساسية (حساسية مفرطة) من الريميفينتانيل أو لأي من مكونات ألتيفا الأخرى(المذكورة في القسم 6 )</li><li>&nbsp;إذا كنت مصاباً بحساسية (حساسية مفرطة) لأي من مسكنات الألم الأخرى المشابهة للفينتانيل والمرتبطة بفئة الأدوية المعروفة بالأفيونات.</li></ul><p>إن لم تكن متأكداً من أن أياً مما ورد أعلاه ينطبق عليك، استشر طبيبك أو الصيدلي أو الممرضة قبل تلقي ألتيفا.</p><p><strong>التحذيرات والاحتياطات</strong><br />استشر طبيبك أو الصيدلي قبل تلقي ألتيفا في الحالات التالية :</p><ul><li>&nbsp;إذا كنت مصاباً بالحساسية (حساسية مفرطة) لأي من أدوية الأفيونات الأخرى، مثل المورفين أو الكودين</li><li>&nbsp;إذا كان عمرك يتجاوز 65 عاما</li><li>&nbsp;إذا كنت مصاباً بالجفاف أو فقدت كمية كبيرة من الدم</li><li>&nbsp;إذا كنت تشعر منذ فترة بالضعف أو الإعياء</li><li>إذا كنت زائد الوزن</li></ul><p>إن لم تكن متأكداً من أن أياً مما ورد أعلاه ينطبق عليك، استشر طبيبك أو الصيدلي أو الممرضة قبل تلقي ألتيفا.</p><p><strong>الأدوية الأخرى وألتيفا</strong><br />أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخراً أو قد تتناول أي أدوية أخرى، بما في ذلك الأدوية التي تصرف بدون وصفة طبية. ويتضمن ذلك الأدوية العشبية أيضاً. هذا لأن ألتيفا يمكن أن يتفاعل مع الأدوية الأخرى ويتسبب في ظهور آثار جانبية.</p><p>أخبر الطبيب أو الصيدلي إن كنت تتناول أيًا من الأدوية التالية على وجه الخصوص:</p><ul><li>&nbsp;أدوية علاج أمراض القلب أو ضغط الدم، مثل حاصرات بيتا (تتضمن هذه الأدوية أتينولول، وميتوبرولول، وكارفيديلول، وبروبانولول وبيزوبرولول) أو حاصرات قناة الكاليسيوم(تتضمن هذه الأدوية أملوديبين، وديلتيازيم ونيفاديباين).</li></ul><p>يتسبب الاستخدام المتزامن لألتيفا والأدوية المهدئة مثل البنزوديازبينات أو الأدوية المشابهة في ارتفاع احتمال التعرض للنعاس، وصعوبات التنفس (نقص التهوية)، والغيوبة وقد يكون مهدداً للحياة. ونظراً لذلك، يجب النظر في اللجوء إلى الاستخدام المتزامن فقط عند تعذر الخيارات العلاجية الأخرى.</p><p>رغم ذلك، إذا وصف لك الطبيب ألتيفا إلى جانب أدوية مهدئة، فيجب أن يحدد الطبيب الجرعة وفترة العلاج المتزامن.</p><p>يُرجى إخبار الطبيب بجميع الأدوية المهدئة التي تتناولها، والالتزام بدقة بالجرعة التي يوصي بها الطبيب. قد يكون من المفيد إخبار الأصدقاء أو الأقارب بالانتباه إلى العلامات والأعراض المذكورة أعلاه. اتصل بطبيبك عند ظهور هذه الأعراض.</p><p><strong>الحمل والرضاعة الطبيعية</strong><br />إذا كنتِ حاملاً أو ترضعين رضاعة طبيعية، أو تعتقدين أنكِ قد تكونين حاملاً أو تخططين للحمل، اطلبي المشورة من طبيبك قبل تلقي هذا الدواء.</p><p><strong>القيادة واستخدام الآلات</strong><br />إذا كنت ستقيم بالمستشفى لبقية اليوم فقط، سيخبرك الطبيب بالمدة التي يجب أن تنتظرها قبل مغادرة المستشفى أو قيادة السيارة. قد يكون خطيراً أن تقود بعد فترة وجيزة من الخضوع للعمليات،</p><p>فقد يؤثر الدواء على قدرتك على القيادة حيث قد يتسبب لك بالنعاس أو الدوّار.</p><ul><li>&nbsp;امتنع عن القيادة أثناء العلاج بهذا الدواء إلى أن تعرف كيفية تأثيره عليك.</li><li>&nbsp;تعد القيادة من الأعمال الإجرامية إذا كان هذا الدواء يؤثر على قدرتك على القيادة.</li><li>&nbsp;إلا أن ذلك لن يعتبر عملاً إجرامياً في الحالات التالية:</li></ul><p>o إذا وُصف لك هذا الدواء لعلاج مشكلة طبية أو سنية،<br />o وإذا تناولته وفقاً لتعليمات الطبيب الذي كتب لك الوصفة الطبية ووفقاً للمعلومات المقدمة مع هذا الدواء<br />o ولم يكن تناوله يؤثر على قدرتك على القيادة بأمان</p><p>تحدث إلى طبيبك أو الصيدلي إن لم تكن متأكداً ما إذا كان من الآمن القيادة أثناء تناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>3-كيفية إعطاء ألتيفا&nbsp;</strong></p><p><strong>كيفية إعطاء الحقن</strong><br />لا يتوقع منك أبداً إعطاء هذا الدواء لنفسك. وسوف يتم إعطاؤه لك دائماً بواسطة شخص مؤهل لذلك.</p><p>يمكن تلقي ألتيفا:</p><ul><li>كحقنة مفردة في الوريد</li><li>كتسريب متواصل في الوريد، وهي الطريقة التي يتم من خلالها تلقي الدواء عبر فترة زمنية أطول.</li></ul><p>تحدد الجرعة والطريقة التي تتلقي بها الدواء بحسب:</p><ul><li>وزنك.</li><li>&nbsp;العملية التي تخضع لها</li><li>&nbsp;درجة الألم الذي ستتعرض له</li><li>&nbsp;درجة التخدير التي يحددها لك الطاقم الطبي في وحدة العناية المركزة.</li></ul><p>تتباين الجرعة من مريض لآخر.</p><p><strong>في حالة تلقي جرعة أكبر مما ينبغي</strong><br />يراقب ظهور آثار ألتيفا بدقة على مدار العملية التي تخضع لها وفي العناية المركزة، ويتخذ الإجراء الأنسب على وجه السرعة إذا تلقيت جرعة أكبر مما ينبغي.</p><p><strong>بعد الانتهاء من العملية</strong><br />أخبر طبيبك أو الممرضة إذا كنت تشعر بالألم. إذا كنت تشعر بالألم بعد الانتهاء من الإجراء، سيتمكن الطاقم الطبي من تقديم مسكنات آلام أخرى لك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p><strong>4-الآثار الجانبية المحتملة</strong><br />مثل جميع الأدوية، يمكن أن يسبب ألتيفا آثاراً جانبية، على الرغم من أنه ليس بالضرورة أن يعاني منها الجميع. قد تحدث الآثار الجانبية التالية مع تناول هذا الدواء.</p><p>من الممكن أن يكون بعض الأشخاص حساسين من ألتيفا. <strong>يجب عليك إبلاغ الطبيب أو الممرضة على الفور في حالة :</strong><br /><strong>نادرة</strong> (قد تؤثر على 1 من كل 1000 شخص)</p><ul><li>&nbsp;أزيز مفاجئ وألم بالصدر أو ضيق الصدر</li><li>&nbsp;تورم الجفنين، أو الوجه، أو الشفتين، أو الفم أو اللسان</li><li>&nbsp;ظهور طفح جلدي مصحوب بتورم أو &quot;شرى&quot; بأي مكان بالجسم</li><li>&nbsp;الانهيار</li></ul><p>أخبر طبيبك فور ملاحظة ظهور أي مما يلي:<br /><strong>شائعة جد ا</strong> (قد تؤثر على أكثر من 1 من كل 10 أشخاص)</p><ul><li>&nbsp;تيبس في العضلات</li><li>انخفاض ضغط الدم</li><li>&nbsp;الشعور بالغثيان أو القيء</li></ul><p><strong>شائعة</strong> (قد تؤثر على 1 من كل 10 أشخاص)</p><ul><li>تباطؤ ضربات القلب</li><li>&nbsp;تنفس ضحل أو انقطاع مؤقت في التنفس</li><li>&nbsp;حكة</li></ul><p><strong>غير شائعة</strong> (قد تؤثر على 1 من كل 100 شخص)</p><ul><li>&nbsp;مشكلات تنفسية (نقص التأكسج)</li><li>&nbsp;إمساك</li></ul><p><strong>نادرة</strong> (قد تؤثر على 1 من كل 1000 شخص)</p><ul><li>&nbsp;ردود فعل تحسسية</li><li>توقف ضربات القلب</li></ul><p><strong>غير معروف</strong> (لا يمكن تقدير مدى التكرار من البيانات المتوفرة)</p><ul><li>&nbsp;الاحتياج الجسدي لدواء ألتيفا )الاعتماد على الدواء( أو الحاجة لرفع الجرعات بمرور الوقت للحصول على التأثير ذاته(تحمل الدواء)</li><li>&nbsp;نوبات (تشنجات)</li><li>&nbsp;نمط من عدم انتظام ضربات القلب(الإحصار الأذيني البطيني)</li></ul><p><strong>تتضمن الآثار الجانبية الأخرى التي قد تظهر عند الإفاقة بعد تلقي أدوية التخدير:</strong></p><p><strong>شائعة </strong>(قد تؤثر على 1 من كل 10 أشخاص):</p><ul><li>ارتعاد</li><li>&nbsp;ارتفاع ضغط الدم</li></ul><p><strong>غير شائعة </strong>(قد تؤثر على 1 من كل 100 شخص)</p><ul><li>&nbsp;آلام</li></ul><p><strong>نادرة </strong>(قد تؤثر على 1 من كل 1000 شخص)</p><ul><li>&nbsp;الشعور بهدوء شديد أو النعاس (سكون)</li></ul><p><strong>آثار جانبية أخرى ظهرت بالتحديد عند الانقطاع المفاجئ عن ألتيفا بعد تلقيه لفترة طويلة تتجاوز 3 أيام</strong></p><ul><li>&nbsp;تسارع ضربات القلب (تسرع القلب)</li><li>&nbsp;ارتفاع ضغط الدم (فرط الضغط)</li><li>&nbsp;تململ (هياج)</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>5-كيفية تخزين ألتيفا</strong></p><ul><li>&nbsp;يُحفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</li><li>&nbsp;لا تستخدم ألتيفا بعد تاريخ انتهاء الصلاحية الموضح على القارورة والعبوة الكرتونية بعد كلمة &quot; EXP &quot; (انتهاء الصلاحية). يشير تاريخ انتهاء الصلاحية إلى آخر يوم من ذلك الشهر.</li><li>&nbsp;لا يُخزن في درجة حرارة أعلى من 25 درجة مئوية.</li><li>&nbsp;يجب استخدام ألتيفا فور تحضيره. لا يجب التخلص من أي محلول غير مستخدم في ماء الصرف الصحي أو مع المخلفات المنزلية. سيتخلص الطبيب أو الممرضة من أي أدوية لم تعد بحاجة إليها. ستساعد هذه الإجراءات في الحفاظ على البيئة.</li><li>&nbsp;يُخزن هذا الدواء في عبوته الأصلية مع النشرة المُرفقة.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>أ. محتويات ألتيفا</strong><br />المادة الفعالة هي ريميفينتانيل هيدروكلوريد.<br />المواد الأخرى هي غليسين وحمض هيدروكلوريك (لضبط درجة الحموضة).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p><strong>ب. كيف يبدو ألتيفا وما هي محتويات العبوة</strong><br />ألتيفا للحقن مسحوق مجفد معقم غير مولد للحمى، خال من المواد الحافظة، لونه ما بين الأبيض إلى الأبيض المائل للصفرة، ويتوفر بالتركيزات التالية:</p><ul><li>1 ملغ ألتيفا للحقن، في قوارير زجاجية 3 مل</li><li>2 ملغ ألتيفا للحقن، في قوارير زجاجية 5 مل</li><li>5 ملغ ألتيفا للحقن، في قوارير زجاجية 10 مل</li></ul><p>يُمزج المسحوق بسائل مناسب قبل الحقن. بعد المزج لإعداد المحلول، يكون ألتيفا رائقاً وعديم اللون.<br />يتم توريد كل تركيز من تركيزات ألتيفا في علب كرتونية تحتوي على 5 قوارير.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>ت. مالك حق التسويق والمُصَّنع</strong></p><p><strong>مالك حق التسويق:</strong><br />شركة أسبن فارما تريدينغ المحدودة، 3016 ليك درايف، مجمع سيتي ويست للأعمال، دبلن 24 ، أيرلندا</p><p><strong>المُصَّنع:</strong><br />غلاسكوسميثكلاين مانيوفاكتشرينج ش.ذ.م.م، سان بولو دي توريل، بارما، إيطاليا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ث. تمت آخر موافقة على هذه النشرة في أغسطس 2019 ، رقم النسخة 002
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ultiva (remifentanil hydrochloride) for Injection 5 mg
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ultiva is a sterile, endotoxin-free, preservative-free, white to off white, lyophilised powder, to be reconstituted before use.

 When reconstituted as directed, solutions of Ultiva are clear and colourless and contain 1 mg/ml of remifentanil base as remifentanil hydrochloride. 

Ultiva for injection is available in glass vials containing 1 mg, 2 mg or 5 mg of remifentanil base.

 For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lyophilised powder for reconstitution for intravenous (IV) administration.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ultiva is indicated as an analgesic agent for use during induction and/or maintenance of general anaesthesia under close supervision.</p><p>Ultiva is indicated for provision of analgesia and sedation in mechanically ventilated intensive care patients 18 years of age and over.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ultiva should be administered only in a setting fully equipped for the monitoring and support of respiratory and cardiovascular function and by persons specifically trained in the use of anaesthetic drugs and the recognition and management of the expected adverse effects of potent opioids, including respiratory and cardiac resuscitation. Such training must include the establishment and maintenance of a patent airway and assisted ventilation.</p><p>Continuous infusions of Ultiva must be administered by a calibrated infusion device into a fast flowing IV line or via a dedicated IV line. This infusion line should be connected at, or close to, the venous cannula and primed, to minimise the potential dead space (see section 6.6 for additional information, including tables with examples of infusion rates by body weight to help titrate Ultiva to the patient&#39;s anaesthetic needs).</p><p>Ultiva may also be given by target controlled infusion (TCI) with an approved infusion device incorporating the Minto pharmacokinetic model with covariates for age and lean body mass (LBM).</p><p>Care should be taken to avoid obstruction or disconnection of infusion lines and to adequately clear the lines to remove residual Ultiva after use (see section 4.4).</p><p>Ultiva is for intravenous use only and must not be administered by epidural or intrathecal injection (see section 4.3).</p><p><strong>Dilution</strong></p><p>Ultiva may be further diluted after reconstitution (see section 6.4 and 6.6 for storage conditions of the reconstituted/diluted product and the recommended diluents).</p><p>For manually-controlled infusion Ultiva can be diluted to concentrations of 20 to 250 micrograms/ml (50 micrograms/ml is the recommended dilution for adults and 20 to 25 micrograms/ml for paediatric patients aged 1 year and over).</p><p>For TCI the recommended dilution of Ultiva is 20 to 50 micrograms/ml.</p><p>(See section 6.6 for additional information, including tables to help titrate Ultiva to the patient&#39;s anaesthetic needs).</p><p><strong>4.2.1 General Anaesthesia</strong></p><p>The administration of Ultiva must be individualised based on the patient&#39;s response. Specific dosing guidelines for patients undergoing cardiac surgery are provided in section 4.2.2 below.</p><p><strong>4.2.1.1. Adults</strong></p><p><strong>Administration by Manually-Controlled Infusion</strong></p><p>The following table summarises the starting infusion rates and dose range:</p><p>DOSING GUIDELINES FOR ADULTS</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p><strong>INDICATION</strong></p></td><td rowspan="2"><p><strong>BOLUS INJECTION</strong></p><p><strong>(micrograms/kg)</strong></p></td><td colspan="2"><p><strong>CONTINUOUS INFUSION</strong></p><p><strong>(micrograms/kg/min)</strong></p></td></tr><tr><td><p><strong>Starting Rate</strong></p></td><td><p><strong>Range</strong></p></td></tr><tr><td><p>Induction of anaesthesia</p></td><td><p>1(give over not less than 30 seconds)</p></td><td><p>0.5 to 1</p></td><td><p>_</p></td></tr><tr><td><p>Maintenance of anaesthesia in ventilated patients</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&bull;&nbsp; Nitrous oxide (66%)</p></td><td><p>0.5 to 1</p></td><td><p>0.4</p></td><td><p>0.1 to 2</p></td></tr><tr><td><p>&bull;&nbsp; Isoflurane (starting dose 0.5MAC)</p></td><td><p>0.5 to 1</p></td><td><p>0.25</p></td><td><p>0.05 to 2</p></td></tr><tr><td><p>&bull;&nbsp; Propofol (Starting dose 100 micrograms/kg/min)</p></td><td><p>0.5 to 1</p></td><td><p>0.25</p></td><td><p>0.05 to 2</p></td></tr></tbody></table><p>When given by bolus injection at induction Ultiva should be administered over not less than 30 seconds.</p><p>At the doses recommended above, remifentanil significantly reduces the amount of hypnotic agent required to maintain anaesthesia. Therefore, isoflurane and propofol should be administered as recommended above to avoid an increase of haemodynamic effects such as hypotension and bradycardia (see Concomitant medication below).</p><p><strong>Induction of anaesthesia:</strong> Ultiva should be administered with a standard dose of an hypnotic agent, such as propofol, thiopentone, or isoflurane, for the induction of anaesthesia. Administering Ultiva after an hypnotic agent will reduce the incidence of muscle rigidity. Ultiva can be administered at an infusion rate of 0.5 to 1 micrograms/kg/min, with or without an initial slow bolus injection of 1 microgram/kg given over not less than 30 seconds. If endotracheal intubation is to occur more than 8 to 10 minutes after the start of the infusion of Ultiva, then a bolus injection is not necessary.</p><p><strong>Maintenance of anaesthesia in ventilated patients:</strong> After endotracheal intubation, the infusion rate of Ultiva should be decreased, according to anaesthetic technique, as indicated in the above table. Due to the fast onset and short duration of action of Ultiva, the rate of administration during anaesthesia can be titrated upward in 25% to 100% increments or downward in 25% to 50% decrements, every 2 to 5 minutes to attain the desired level of mu-opioid response. In response to light anaesthesia, supplemental slow bolus injections may be administered every 2 to 5 minutes.</p><p><strong>Anaesthesia in spontaneously breathing anaesthetised patients with a secured airway (e.g. laryngeal mask anaesthesia):</strong>In spontaneously breathing anaesthetised patients with a secured airway respiratory depression is likely to occur. Special care is needed to adjust the dose to the patient requirements and ventilatory support may be required. The recommended starting infusion rate for supplemental analgesia in spontaneously breathing anaesthetised patients is 0.04 micrograms/kg/min with titration to effect. A range of infusion rates from 0.025 to 0.1 micrograms/kg/min has been studied. Bolus injections are not recommended in spontaneously breathing anaesthetised patients.</p><p>Ultiva should not be used as an analgesic in procedures where patients remain conscious or do not receive any airway support during the procedure.</p><p><strong>Concomitant medication:</strong> Ultiva decreases the amounts or doses of inhaled anaesthetics, hypnotics and benzodiazepines required for anaesthesia (see section 4.5).</p><p>Doses of the following agents used in anaesthesia: isoflurane, thiopentone, propofol and temazepam have been reduced by up to 75% when used concurrently with remifentanil.</p><p><strong>Guidelines for discontinuation/continuation into the immediate post-operative period:</strong> Due to the very rapid offset of action of Ultiva no residual opioid activity will be present within 5 to 10 minutes after discontinuation. For those patients undergoing surgical procedures where post-operative pain is anticipated, analgesics should be administered prior to discontinuation of Ultiva. Sufficient time must be allowed to reach the maximum effect of the longer acting analgesic. The choice of analgesic should be appropriate for the patient&#39;s surgical procedure and the level of post-operative care.</p><p>Care should be taken to avoid inadvertent administration of Ultiva remaining in IV lines and cannulae (see section 4.4).</p><p>In the event that longer acting analgesia has not been established prior to the end of surgery, Ultiva may need to be continued to maintain analgesia during the immediate post-operative period until longer acting analgesia has reached its maximum effect.</p><p>Guidance on provision of analgesia and sedation in mechanically ventilated intensive care patients is provided in section 4.2.3 below.</p><p>In patients who are breathing spontaneously, the infusion rate of Ultiva should initially be decreased to a rate of 0.1 micrograms/kg/min. The infusion rate may then be increased or decreased by not greater than 0.025 micrograms/kg/min every five minutes, to balance the patient&#39;s level of analgesia and respiratory rate. Ultiva should only be used in a setting fully equipped for the monitoring and support of respiratory and cardiovascular function, under the close supervision of persons specifically trained in the recognition and management of the respiratory effects of potent opioids.</p><p>The use of bolus injections of Ultiva to treat pain during the post-operative period is not recommended in patients who are breathing spontaneously.</p><p><strong>Administration by Target-Controlled Infusion </strong></p><p><strong>Induction and maintenance of anaesthesia in ventilated patients:</strong> Ultiva TCI should be used in association with an intravenous or inhalational hypnotic agent during the induction and maintenance of anaesthesia in ventilated adult patients (see the table in Dosing Guidelines For Adults under 4.2.1.1). In association with these agents, adequate analgesia for induction of anaesthesia and surgery can generally be achieved with target blood remifentanil concentrations ranging from 3 to 8 nanograms/ml. Ultiva should be titrated to individual patient response. For particularly stimulating surgical procedures target blood concentrations up to 15 nanograms/ml may be required.</p><p>At the doses recommended above, remifentanil significantly reduces the amount of hypnotic agent required to maintain anaesthesia. Therefore, isoflurane and propofol should be administered as recommended above to avoid an increase of haemodynamic effects such as hypotension and bradycardia (see Table and Concomitant medication subsection in 4.2.1.1).</p><p>For information on blood remifentanil concentrations achieved with manually-controlled infusion see Table 6.</p><p>There are insufficient data to make recommendations on the use of TCI for spontaneous ventilation anaesthesia.</p><p><strong>Guidelines for discontinuation/continuation into the immediate post-operative period:</strong> At the end of surgery when the TCI infusion is stopped or the target concentration reduced, spontaneous respiration is likely to return at calculated remifentanil concentrations in the region of 1 to 2 nanograms/ml. As with manually-controlled infusion, post-operative analgesia should be established before the end of surgery with longer acting analgesics (see Guidelines for discontinuation under Administration by manually-controlled infusion in section 4.2.1.1)</p><p>As there are insufficient data, the administration of Ultiva by TCI for the management of post-operative analgesia is not recommended.</p><p><strong>4.2.1.2 Paediatric patients (1 to 12 years of age)</strong></p><p>Co-administration of Ultiva and an intravenous anaesthetic agent for induction of anaesthesia has not been studied in detail and is therefore not recommended.</p><p>Ultiva TCI has not been studied in paediatric patients and therefore administration of Ultiva by TCI is not recommended in these patients.</p><p>When given by bolus injection Ultiva should be administered over not less than 30 seconds. Surgery should not commence until at least 5 minutes after the start of the Ultiva infusion, if a simultaneous bolus dose has not been given. For sole administration of nitrous oxide (70%) with Ultiva, typical maintenance infusion rates should be between 0.4 and 3 micrograms/kg/min, and although not specifically studied, adult data suggest that 0.4 micrograms/kg/min is an appropriate starting rate. Paediatric patients should be monitored and the dose titrated to the depth of analgesia appropriate for the surgical procedure.</p><p><strong>Induction of anaesthesia: </strong>The use of remifentanil for induction of anaesthesia in patients aged 1 to 12 years is not recommended as there are no data available in this patient population.</p><p><strong>Maintenance of anaesthesia:</strong> The following doses of Ultiva are recommended for maintenance of anaesthesia:</p><p>DOSING GUIDELINES FOR PAEDIATRIC PATIENTS (1 to 12 years of age)</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p><strong>*CONCOMITANT ANAESTHETIC AGENT</strong></p></td><td rowspan="2"><p><strong>BOLUS INJECTION</strong></p><p><strong>(micrograms/kg)</strong></p></td><td colspan="2"><p><strong>CONTINUOUS INFUSION</strong></p><p><strong>(micrograms/kg/min)</strong></p></td></tr><tr><td><p><strong>Starting Rate</strong></p></td><td><p><strong>Range</strong></p></td></tr><tr><td><p>Halothane (starting dose 0.3MAC)</p></td><td><p>1</p></td><td><p>0.25</p></td><td><p>0.05 to 1.3</p></td></tr><tr><td><p>Sevoflurane (starting dose 0.3MAC)</p></td><td><p>1</p></td><td><p>0.25</p></td><td><p>0.05 to 0.9</p></td></tr><tr><td><p>Isoflurane (starting dose 0.5MAC)</p></td><td><p>1</p></td><td><p>0.25</p></td><td><p>0.06 to 0.9</p></td></tr></tbody></table><p>*co-administered with nitrous oxide/oxygen in a ratio of 2:1</p><p><strong>Concomitant medication:</strong> At the doses recommended above, remifentanil significantly reduces the amount of hypnotic agent required to maintain anaesthesia. Therefore, isoflurane, halothane and sevoflurane should be administered as recommended above to avoid an increase of haemodynamic effects such as hypotension and bradycardia. No data are available for dosage recommendations for simultaneous use of other hypnotics other than those listed in the table with remifentanil (see section 4.2.1.1Adults- Concomitant medication).</p><p><strong>Guidelines for patient management in the immediate post-operative period/ Establishment of alternative analgesia prior to discontinuation of Ultiva:</strong> Due to the very rapid offset of&nbsp;action of Ultiva, no residual activity will be present within 5 to 10 minutes after discontinuation. For those patients undergoing surgical procedures where post-operative pain is anticipated, analgesics should be administered prior to discontinuation of Ultiva. Sufficient time must be allowed to reach the therapeutic effect of the longer acting analgesic. The choice of agent(s), the dose and the time of administration should be planned in advance and individually tailored to be appropriate for the patient&#39;s surgical procedure and the level of post-operative care anticipated (see section 4.4).</p><p><strong>4.2.1.3 Neonates/infants (aged less than 1 year): </strong></p><p>There is limited clinical trial experience of remifentanil in neonates and infants (aged under 1 year old; see section 5.1). The pharmacokinetic profile of remifentanil in neonates/infants (aged less than 1 year) is comparable to that seen in adults after correction for body weight differences (see section 5.2). However, because there are insufficient clinical data, the administration of Ultiva is not recommended for this age group.</p><p>Use for Total Intravenous anaesthesia (TIVA): There is limited clinical trial experience of remifentanil of TIVA in infants (see section 5.1). However, there are insufficient clinical data to make dosage recommendations.</p><p><strong>4.2.2 Cardiac anaesthesia</strong></p><p><strong>Administration by Manually-Controlled Infusion</strong></p><p>DOSING GUIDELINES FOR CARDIAC ANAESTHESIA</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p><strong>&nbsp;</strong></p><p><strong>INDICATION</strong></p></td><td rowspan="2"><p><strong>&nbsp;</strong></p><p><strong>BOLUS INJECTION</strong></p><p><strong>(micrograms/kg)</strong></p></td><td colspan="2"><p><strong>CONTINUOUS INFUSION</strong></p><p><strong>(micrograms/kg/min)</strong></p></td></tr><tr><td><p><strong>Starting Rate</strong></p></td><td><p><strong>Range</strong></p></td></tr><tr><td><p>Induction of anaesthesia</p></td><td><p>Not recommended</p></td><td><p>1</p></td><td><p>_</p></td></tr><tr><td><p>Maintenance of anaesthesia in ventilated patients:</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&bull;&nbsp; Isoflurane</p><p>(starting dose 0.4MAC)</p></td><td><p>0.5 to 1</p></td><td><p>1</p></td><td><p>0.003 to 4</p></td></tr><tr><td><p>&bull;&nbsp; Propofol (Starting dose 50micrograms/kg/min)</p></td><td><p>0.5 to 1</p></td><td><p>1</p></td><td><p>0.01 to 4.3</p></td></tr><tr><td><p>Continuation of post-operative analgesia, prior to extubation</p></td><td><p>Not recommended</p></td><td><p>1</p></td><td><p>0 to 1</p></td></tr></tbody></table><p><strong>Induction period of anaesthesia:</strong> After administration of hypnotic to achieve loss of consciousness, Ultiva should be administered at an initial infusion rate of 1 microgram/kg/min. The use of bolus injections of Ultiva during induction in cardiac surgical patients is not recommended. Endotracheal intubation should not occur until at least 5 minutes after the start of the infusion.</p><p><strong>Maintenance period of anaesthesia:</strong> After endotracheal intubation the infusion rate of Ultiva can be titrated upward in 25% to 100% increments, or downward in 25% to 50% decrements, every 2 to 5 minutes according to patient need. Supplemental slow bolus doses, administered over not less than 30 seconds, may also be given every 2 to 5 minutes as required. High risk cardiac patients, such as those with poor ventricular function or undergoing valve surgery, should be administered a maximum bolus dose of 0.5 micrograms/kg. These dosing recommendations also apply during hypothermic cardiopulmonary bypass (see section 5.2).</p><p><strong>Concomitant medication:</strong> At the doses recommended above, remifentanil significantly reduces the amount of hypnotic agent required to maintain anaesthesia. Therefore, isoflurane and propofol should be administered as recommended above to avoid excessive depth of anaesthesia. No data are available for dosage recommendations for simultaneous use of other hypnotics other than those listed in the table with remifentanil (see section 4.2.1.1 Adults - Concomitant medication).</p><p><strong>Guidelines for post-operative patient management </strong></p><p><strong>Continuation of Ultiva post-operatively to provide analgesia prior to weaning for extubation:</strong> It is recommended that the infusion of Ultiva should be maintained at the final intra-operative rate during transfer of patients to the post-operative care area. Upon arrival into this area, the patient&#39;s level of analgesia and sedation should be closely monitored and the Ultiva infusion rate adjusted to meet the individual patient&#39;s requirements (see section 4.2.3 for further information on management of intensive care patients).</p><p><strong>Establishment of alternative analgesia prior to discontinuation of Ultiva:</strong> Due to the very rapid offset of action of Ultiva, no residual opioid activity will be present within 5 to 10 minutes after discontinuation. Prior to discontinuation of Ultiva, patients must be given alternative analgesic and sedative agents at a sufficient time in advance to allow the therapeutic effects of these agents to become established. It is therefore recommended that the choice of agent(s), the dose and the time of administration are planned, before weaning the patient from the ventilator.</p><p><strong>Guidelines for discontinuation of Ultiva:</strong> Due to the very rapid offset of action of Ultiva, hypertension, shivering and aches have been reported in cardiac patients immediately following discontinuation of Ultiva (see section 4.8). To minimise the risk of these occurring, adequate alternative analgesia must be established (as described above), before the Ultiva infusion is discontinued. The infusion rate should be reduced by 25% decrements in at least 10-minute intervals until the infusion is discontinued. During weaning from the ventilator the Ultiva infusion should not be increased and only down titration should occur, supplemented as required with alternative analgesics. Haemodynamic changes such as hypertension and tachycardia should be treated with alternative agents as appropriate.</p><p><strong>When other opioid agents are administered as part of the regimen for transition to alternative analgesia, the patient must be carefully monitored. The benefit of providing adequate post-operative analgesia must always be balanced against the potential risk of respiratory depression with these agents.</strong></p><p><strong>Administration by Target-Controlled Infusion</strong></p><p><strong>Induction and maintenance of anaesthesia:</strong> Ultiva TCI should be used in association with an intravenous or inhalational hypnotic agent during the induction and maintenance of anaesthesia in ventilated adult patients (see table in Dosing Guidelines for Cardiac Anaesthesia under 4.2.2). In association with these agents, adequate analgesia for cardiac surgery is generally achieved at the higher end of the range of target blood remifentanil concentrations used for general surgical procedures. Following titration of remifentanil to individual patient response, blood concentrations as high as 20 nanograms/ml have been used in clinical studies. At the doses recommended above, remifentanil significantly reduces the amount of hypnotic agent required to maintain anaesthesia. Therefore, isoflurane and propofol should be administered as recommended above to avoid an increase of haemodynamic effects such as hypotension and bradycardia (see Table and Concomitant medication subsection in 4.2.2).</p><p>For information on blood remifentanil concentrations achieved with manually-controlled infusion see Table 6.</p><p><strong>Guidelines for discontinuation/continuation into the immediate post-operative period:</strong></p><p>At the end of surgery when the TCI infusion is stopped or the target concentration reduced, spontaneous respiration is likely to return at calculated remifentanil concentrations in the region of 1 to 2 nanograms/ml. As with manually-controlled infusion, post-operative analgesia should be established before the end of surgery with longer acting analgesics (see Guidelines for discontinuation under Administration by manually-controlled infusion in section 4.2.2.)</p><p>As there are insufficient data, the administration of Ultiva by TCI for the management of post-operative analgesia is not recommended.</p><p><strong>4.2.3 Use in Intensive Care </strong></p><p>Ultiva can be used for the provision of analgesia in mechanically ventilated intensive care patients. Sedative agents should be added as appropriate.</p><p>Ultiva has been studied in mechanically ventilated intensive care patients in well controlled clinical trials for up to three days. As patients were not studied beyond three days, no evidence of safety and efficacy for longer treatment has been established. Therefore, the use of Ultiva is not recommended for a duration of treatment greater than 3 days.</p><p>Ultiva TCI has not been studied in intensive care patients and therefore administration of Ultiva by TCI is not recommended in these patients.</p><p>In adults, it is recommended that Ultiva is initiated at an infusion rate of 0.1 micrograms/kg/min (6 micrograms/kg/h) to 0.15 micrograms/kg/min (9 micrograms/kg/h). The infusion rate should be titrated in increments of 0.025 micrograms/kg/min (1.5 micrograms/kg/h) to achieve the desired level of sedation and analgesia. A period of at least 5 minutes should be allowed between dose adjustments. The level of sedation and analgesia should be carefully monitored, regularly reassessed and the Ultiva infusion rate adjusted accordingly. If an infusion rate of 0.2 micrograms/kg/min (12 micrograms/kg/h) is reached and&nbsp; the desired level of sedation is not achieved, it is recommended that dosing with an appropriate sedative agent is initiated (see below). The dose of sedative agent should be titrated to obtain the desired level of sedation. Further increases to the Ultiva infusion rate in increments of 0.025 micrograms/kg/min (1.5 micrograms/kg/h) may be made if additional analgesia is required.</p><p>The following table summarises the starting infusion rates and typical dose range for provision of analgesia and sedation in individual patients:</p><p>DOSING GUIDELINES FOR USE OF ULTIVA WITHIN THE INTENSIVE CARE SETTING</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2"><p>CONTINUOUS INFUSION micrograms/kg/min (micrograms/kg/h)</p></td></tr><tr><td><p>Starting Rate</p></td><td><p>Range</p></td></tr><tr><td><p>0.1 (6) to 0.15 (9)</p></td><td><p>0.006 (0.36) to 0.74 (44.4)</p></td></tr></tbody></table><p>Bolus doses of Ultiva are not recommended in the intensive care setting.</p><p>The use of Ultiva will reduce the dosage requirement of any concomitant sedative agents. Typical starting doses for sedative agents, if required, are given below:</p><p>RECOMMENDED STARTING DOSE OF SEDATIVE AGENTS, IF REQUIRED</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Sedative Agent</p></td><td><p>Bolus (mg/kg)</p></td><td><p>Infusion (mg/kg/h)</p></td></tr><tr><td><p>Propofol</p></td><td><p>Up to 0.5</p></td><td><p>0.5</p></td></tr><tr><td><p>Midazolam</p></td><td><p>Up to 0.03</p></td><td><p>0.03</p></td></tr></tbody></table><p>To allow separate titration of the respective agents, sedative agents should not be prepared as one mixture in the same infusion bag.</p><p><strong>Additional analgesia for ventilated patients undergoing stimulating procedures:</strong> An increase in the existing Ultiva infusion rate may be required to provide additional analgesic cover for ventilated patients undergoing stimulating and/or painful procedures such as endotracheal suctioning, wound dressing and physiotherapy. It is recommended that an Ultiva infusion rate of at least 0.1 micrograms/kg/min (6 micrograms/kg/h) should be maintained for at least 5 minutes prior to the start of the stimulating procedure. Further dose adjustments may be made every 2 to 5 minutes in increments of 25%-50% in anticipation of, or in response to, additional requirement for analgesia. A mean infusion rate of 0.25 micrograms/kg/min (15 micrograms/kg/h), maximum 0.75 micrograms/kg/min (45 micrograms/kg/h), has been administered for provision of additional analgesia during stimulating procedures.</p><p><strong>Establishment of alternative analgesia prior to discontinuation of Ultiva:</strong> Due to the very rapid offset of action of Ultiva, no residual opioid activity will be present within 5 to 10 minutes after discontinuation regardless of the duration of infusion. Following administration of Ultiva, the possibility of tolerance and hyperalgesia should be considered. Therefore, prior to discontinuation of Ultiva, patients must be given alternative analgesic and sedative agents to prevent hyperalgesia and associated haemodynamic changes. These agents must be given at a sufficient time in advance to allow the therapeutic effects of these agents to become established. The range of options for analgesia includes long acting oral, intravenous, or&nbsp;regional analgesics controlled by the nurse or the patient. These techniques should always be titrated to individual patient needs as the infusion of Ultiva is reduced. It is recommended that the choice of agent(s), the dose, and the time of administration are planned prior to discontinuation of Ultiva.</p><p>There is a potential for the development of tolerance with time during prolonged administration of mu-opioid agonists.</p><p><strong>Guidelines for extubation and discontinuation of Ultiva: </strong>In order to ensure a smooth emergence from an Ultiva-based regimen it is recommended that the infusion rate of Ultiva is titrated in stages to 0.1 micrograms/kg/min (6 micrograms/kg/h) over a period up to 1 hour prior to extubation.</p><p>Following extubation, the infusion rate should be reduced by 25% decrements in at least 10-minute intervals until the infusion is discontinued. During weaning from the ventilator the Ultiva infusion should not be increased and only down titration should occur, supplemented as required with alternative analgesics.</p><p>Upon discontinuation of Ultiva, the IV cannula should be cleared or removed to prevent subsequent inadvertent administration.</p><p><strong>When other opioid agents are administered as part of the regimen for transition to alternative analgesia, the patient must be carefully monitored. The benefit of providing adequate analgesia must always be balanced against the potential risk of respiratory depression.</strong></p><p><strong>4.2.3.1 Paediatric intensive care patients </strong></p><p>The use of remifentanil in intensive care patients under the age of 18 years is not recommended as there are no data available in this patient population.</p><p><strong>4.2.3.2 Renally-impaired intensive care patients</strong></p><p>No adjustments to the doses recommended above are necessary in renally-impaired patients, including those undergoing renal replacement therapy; however the clearance of the carboxylic acid metabolite is reduced in patients with renal impairment (see section 5.2).</p><p><strong>4.2.4 Special patient populations </strong></p><p><strong>4.2.4.1 Elderly (over 65 years of age)</strong></p><p><strong>General anaesthesia: </strong>The initial starting dose of remifentanil administered to patients over 65 should be half the recommended adult dose and then shall be titrated to individual patient need as an increased sensitivity to the pharmacological effects of remifentanil has been seen in this patient population. This dose adjustment applies to use in all phases of anaesthesia including induction, maintenance, and immediate post-operative analgesia.</p><p>Because of the increased sensitivity of elderly patients to Ultiva, when administering Ultiva by TCI in this population the initial target concentration should be 1.5 to 4 nanograms/ml with subsequent titration to response.</p><p><strong>Cardiac anaesthesia:</strong> No initial dose reduction is required (see section 4.2.2.).</p><p><strong>Intensive Care:</strong> No initial dose reduction is required (see section 4.2.3.).</p><p><strong>4.2.4.2 Obese patients </strong></p><p>For manually-controlled infusion it is recommended that for obese patients the dosage of Ultiva should be reduced and based upon ideal body weight as the clearance and volume of distribution of remifentanil are better correlated with ideal body weight than actual body weight.</p><p>With the calculation of lean body mass (LBM) used in the Minto model, LBM is likely to be underestimated in female patients with a body mass index (BMI) greater than 35 kg/m2 and in male patients with BMI greater than 40 kg/m2. To avoid underdosing in these patients, remifentanil TCI should be titrated carefully to individual response.</p><p><strong>4.2.4.3 Renal impairment </strong></p><p>On the basis of investigations carried out to date, a dose adjustment in patients with impaired renal function, including intensive care patients, is not necessary.</p><p><strong>4.2.4.4 Hepatic impairment</strong></p><p>Studies carried out with a limited number of patients with impaired liver function, do not justify any special dosage recommendations. However, patients with severe hepatic impairment may be slightly more sensitive to the respiratory depressant effects of remifentanil (see section 4.4). These patients shall be closely monitored and the dose of remifentanil shall be titrated to individual patient need.</p><p><strong>4.2.4.5 Neurosurgery </strong></p><p>Limited clinical experience in patients undergoing neurosurgery has shown that no special dosage recommendations are required.</p><p><strong>4.2.4.6 ASA III/IV patients</strong></p><p><strong>General anaesthesia:</strong> As the haemodynamic effects of potent opioids can be expected to be more pronounced in ASA III/IV patients, caution should be exercised in the administration of Ultiva in this population. Initial dosage reduction and subsequent titration to effect is therefore recommended. In paediatric patients, there are insufficient data to make a dosage recommendation.</p><p>For TCI, a lower initial target of 1.5 to 4 nanograms/ml should be used in ASA III or IV patients and subsequently titrated to response.</p><p><strong>Cardiac anaesthesia:</strong> No initial dose reduction is required (see section 4.2.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                As glycine is present in the formulation, Ultiva is contraindicated for epidural and intrathecal use.

Ultiva is contraindicated in patients with known hypersensitivity to any component of the preparation and other fentanyl analogues.

 Ultiva is contraindicated for use as the sole agent for induction of anaesthesia.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ultiva should be administered only in a setting fully equipped for the monitoring and support of respiratory and cardiovascular function, and by persons specifically trained in the use of anaesthetic drugs and the recognition and management of the expected adverse effects of potent opioids, including respiratory and cardiac resuscitation. Such training must include the establishment and maintenance of a patent airway and assisted ventilation. The use of Ultiva in mechanically ventilated intensive care patients is not recommended for a duration of treatment greater than 3 days.</p><p>Patients with a known hypersensitivity to opioids of a different class may exhibit a hypersensitivity reaction following administration of Ultiva. Caution should be exercised before using Ultiva in these patients.</p><p><strong>Rapid offset of action /Transition to alternative analgesia</strong></p><p>Due to the very rapid offset of action of Ultiva, no residual opioid activity will be present within 5 to 10 minutes after the discontinuation of Ultiva. For those patients undergoing surgical procedures where post-operative pain is anticipated, analgesics should be administered prior to discontinuation of Ultiva. The possibility of tolerance, hyperalgesia and associated haemodynamic changes should be considered when used in Intensive Care Unit. Prior to discontinuation of Ultiva, patients must be given alternative analgesic and sedative agents. Sufficient time must be allowed to reach the therapeutic effect of the longer acting analgesic. The choice of agent(s), the dose and the time of administration should be planned in advance and individually tailored to be appropriate for the patient&#39;s surgical procedure and the level of post-operative care anticipated. When other opioid agents are administered as part of the regimen for transition to alternative analgesia, the benefit of providing adequate post-operative analgesia must always be balanced against the potential risk of respiratory depression with these agents.</p><p><strong>Discontinuation of Treatment </strong></p><p>Symptoms following withdrawal of Ultiva including tachycardia, hypertension and agitation have been reported infrequently upon abrupt cessation, particularly after prolonged administration of more than 3 days. Where reported, re-introduction and tapering of the infusion has been beneficial. The use of Ultiva in mechanically ventilated intensive care patients is not recommended for duration of treatment greater than 3 days.</p><p><strong>Inadvertent administration </strong></p><p>A sufficient amount of Ultiva may be present in the dead space of the IV line and/or cannula to cause respiratory depression, apnoea and/or muscle rigidity if the line is flushed with IV fluids or other drugs. This may be avoided by administering Ultiva into a fast flowing IV line or via a dedicated IV line which is removed when Ultiva is discontinued.</p><p><strong>Muscle rigidity - prevention and management </strong></p><p>At the doses recommended muscle rigidity may occur. As with other opioids, the incidence of muscle rigidity is related to the dose and rate of administration. Therefore, bolus injections should be administered over not less than 30 seconds.</p><p>Muscle rigidity induced by remifentanil must be treated in the context of the patient&#39;s clinical condition with appropriate supporting measures including ventilatory support. Excessive muscle rigidity occurring during the induction of anaesthesia should be treated by the administration of a neuromuscular blocking agent and/or additional hypnotic agents. Muscle rigidity seen during the use of remifentanil as an analgesic may be treated by stopping or decreasing the rate of administration of remifentanil. Resolution of muscle rigidity after discontinuing the infusion of remifentanil occurs within minutes. Alternatively an opioid antagonist may be administered, however this may reverse or attenuate the analgesic effect of remifentanil.</p><p><strong>Respiratory depression &ndash; prevention and management </strong></p><p>As with all potent opioids, profound analgesia is accompanied by marked respiratory depression. Therefore, remifentanil should only be used in areas where facilities for monitoring and dealing with respiratory depression are available. The appearance of respiratory depression should be managed appropriately, including decreasing the rate of infusion by 50%, or by a temporary discontinuation of the infusion. Unlike other fentanyl analogues, remifentanil has not been shown to cause recurrent respiratory depression even after prolonged administration. However, as many factors may affect post-operative recovery it is important to ensure that full consciousness and adequate spontaneous ventilation are achieved before the patient is discharged from the recovery area.</p><p><strong>Cardiovascular effects </strong></p><p>The risk of cardiovascular effects such as hypotension and bradycardia (see section 4.8), which may rarely lead to asystole/cardiac arrest may be reduced by lowering the rate of infusion of Ultiva or the dose of concurrent anaesthetics or by using IV fluids, vasopressor or anticholinergic agents as appropriate.</p><p>Debilitated, hypovolaemic, and elderly patients may be more sensitive to the cardiovascular effects of remifentanil.</p><p><strong>Neonates/infants </strong></p><p>There is limited data available on use in neonates/infants under 1 year of age (see sections 4.2.1.3 and 5.1).</p><p><strong>Drug abuse</strong></p><p>As with other opioids remifentanil may produce dependency.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Remifentanil is not metabolised by plasmacholinesterase, therefore, interactions with drugs metabolised by this enzyme are not anticipated.</p><p>As with other opioids, remifentanil, whether given by manually-controlled infusion or TCI, decreases the amounts or doses of inhaled and IV anaesthetics, and benzodiazepines required for anaesthesia (see section 4.2 Posology and method of administration, General Anaesthesia &ndash; Adults, Paediatric Patients, and Cardiac Surgery). If doses of concomitantly administered CNS depressant drugs are not reduced, patients may experience an increased incidence of adverse effects associated with these agents.</p><p>The cardiovascular effects of Ultiva (hypotension and bradycardia), may be exacerbated in patients receiving concomitant cardiac depressant drugs, such as beta-blockers and calcium channel blocking agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no adequate and well-controlled studies in pregnant women. Ultiva should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.</p><p>It is not known whether remifentanil is excreted in human milk. However, because fentanyl analogues are excreted in human milk and remifentanil-related material was found in rat milk after dosing with remifentanil, nursing mothers should be advised to discontinue breast feeding for 24 hours following administration of remifentanil.</p><p>For a summary of the reproductive toxicity study findings please refer to Section 5.3 Preclinical safety data.</p><p><strong>Labour and delivery</strong></p><p>The safety profile of remifentanil during labour or delivery has not been demonstrated. There are insufficient data to recommend remifentanil for use during labour and Caesarean section. Remifentanil crosses the placental barrier and fentanyl analogues can cause respiratory depression in the child.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>After anaesthesia with remifentanil the patient should not drive or operate machinery. The physician should decide when these activities may be resumed. It is advisable that the patient is accompanied when returning home and that alcoholic drink is avoided.</p><p>This medicine can impair cognitive function and can affect a patient&#39;s ability to drive safely. This class of medicine is in the list of drugs included in regulations under 5a of the Road Traffic Act 1988. When prescribing this medicine, patients should be told:</p><p>&bull; The medicine is likely to affect your ability to drive</p><p>&bull; Do not drive until you know how the medicine affects you</p><p>&bull; It is an offence to drive while under the influence of this medicine</p><p>&bull; However, you would not be committing an offence (called &#39;statutory defence&#39;) if:</p><p>o The medicine has been prescribed to treat a medical or dental problem and</p><p>o You have taken it according to the instructions given by the prescriber and in the information provided with the medicine and</p><p>o It was not affecting your ability to drive safely</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most common undesirable effects associated with remifentanil are direct extensions of mu-opioid agonist pharmacology. These adverse events resolve within minutes of discontinuing or decreasing the rate of remifentanil administration. The frequencies below are defined as very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000) and very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><p>Immune System Disorders<br /><strong>Rare:</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Allergic reactions including anaphylaxis have been reported in patients receiving remifentanil in conjunction with one or more&nbsp; anaesthetic agents.</p><p><strong>Psychiatric disorders</strong><br />Not known:&nbsp; &nbsp;Drug dependence</p><p><strong>Nervous System Disorders</strong><br />Very common:&nbsp; Skeletal muscle rigidity<br />Rare:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Sedation (during recovery from general anaesthesia)</p><p><strong>Not known:&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong>Convulsions</p><p><strong>Cardiac Disorders</strong></p><p>Common:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Bradycardia<br />Rare:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Asystole/cardiac arrest, usually preceded by bradycardia, has been reported in patients receiving remifentanil in&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; conjunction with other anaesthetic agents.</p><p><strong>Not known:</strong>&nbsp; &nbsp; &nbsp; Atrioventricular block</p><p><strong>Vascular Disorders</strong><br />Very common:&nbsp; Hypotension<br />Common:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Post-operative hypertension</p><p><strong>Respiratory, Thoracic and Mediastinal Disorders</strong></p><p>Common:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Acute respiratory depression, apnoea<br />Uncommon:&nbsp; &nbsp; &nbsp;Hypoxia</p><p><strong>Gastrointestinal Disorders</strong><br />Very common:&nbsp; &nbsp;Nausea, vomiting<br />Uncommon:&nbsp; &nbsp; &nbsp; &nbsp;Constipation</p><p>Skin and Subcutaneous Tissue Disorders<br />Common:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Pruritus</p><p><strong>General Disorders and Administration Site Conditions</strong><br />Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Post-operative shivering<br />Uncommon:&nbsp;&nbsp;&nbsp;Post-operative aches<br />Not known:&nbsp;&nbsp;&nbsp;&nbsp;Drug tolerance</p><p><strong>Discontinuation of treatment</strong></p><p>Symptoms following withdrawal of remifentanil including tachycardia, hypertension and agitation have been reported infrequently upon abrupt cessation, particularly after prolonged administration of more than 3 days (see section 4.4).</p><p><strong>To report any side effect(s):<br />- Saudi Arabia:</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td>- The National Pharmacovigilance and Drug Safety Centre (NPC):<br />- Fax: 00966112057662<br />- Call NPC at 00966112038222, Exts: 2317-2356-2353-2354-2334-2340.<br />- Toll free phone: 8002490000<br />- E-mail: npc.drug@sfda.gov.sa<br />- Website: www.sfda.gov.sa/npc</td></tr></tbody></table><p><strong>- Other GCC States:</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td>Please contact the relevant competent authority.</td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As with all potent opioid analgesics, overdose would be manifested by an extension of the pharmacologically predictable actions of remifentanil. Due to the very short duration of action of Ultiva, the potential for deleterious effects due to overdose is limited to the immediate time period following drug administration. Response to discontinuation of the drug is rapid, with return to baseline within ten minutes.</p><p>In the event of overdose, or suspected overdose, take the following actions: discontinue administration of Ultiva, maintain a patent airway, initiate assisted or controlled ventilation with oxygen, and maintain adequate cardiovascular function. If depressed respiration is associated with muscle rigidity, a neuromuscular blocking agent may be required to facilitate assisted or controlled respiration. Intravenous fluids and vasopressor agents for the treatment of hypotension and other supportive measures may be employed.</p><p>Intravenous administration of an opioid antagonist such as naloxone may be given as a specific antidote in addition to ventilatory support to manage severe respiratory depression. The duration of respiratory depression following overdose with Ultiva is unlikely to exceed the duration of action of the opioid antagonist.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Opioid anaesthetics, ATC code:N01AH06</p><p>Remifentanil is a selective mu-opioid agonist with a rapid onset and very short duration of action. The mu-opioid activity, of remifentanil, is antagonised by narcotic antagonists, such as naloxone.</p><p>Assays of histamine in patients and normal volunteers have shown no elevation in histamine levels after administration of remifentanil in bolus doses up to 30 micrograms/kg.</p><p>Neonates/infants (aged less than 1 year):</p><p>In a randomised (ratio of 2:1, remifentanil:halothane), open label, parallel group, multicentre study in 60 young infants and neonates &le;8 weeks of age (mean 5.5 weeks) with an ASA physical status of I-II who were undergoing pyloromyotomy, the efficacy and safety of remifentanil (given as a 0.4 &mu;g/kg/min initial continuous infusion plus supplemental doses or infusion rate changes as needed) was compared with halothane (given at 0.4% with supplemental increases as needed). Maintenance of anaesthesia was achieved by the additional administration of 70% nitrous oxide (N20) plus 30% oxygen. Recovery times were superior in the remifentanil relative to the halothane groups (not significant).</p><p>Use for Total Intravenous anaesthesia (TIVA) - children aged 6 months to 16 years</p><p>TIVA with remifenanil in paediatric surgery was compared to inhalation anaesthesia in three randomised, open-label studies. The results are summarised in the table below.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Surgical intervention</strong></p></td><td><p><strong>Age (y), (N)</strong></p></td><td><p><strong>Study condition (maintenance)</strong></p></td><td><p><strong>Extubation (min) (mean (SD)</strong></p></td></tr><tr><td rowspan="2"><p>Lower abdominal/urological surgery</p></td><td rowspan="2"><p>0.5-16</p><p>(120)</p></td><td><p>TIVA: propofol (5 - 10 mg/kg/h) + remifentanil (0.125 - 1.0 &mu;g/kg/min)</p></td><td><p>11.8 (4.2)</p></td></tr><tr><td><p>Inhalation anaesthesia:</p><p>sevoflurane (1.0 - 1.5 MAC) and</p><p>remifentanil (0.125 - 1.0 &mu;g/kg/min)</p></td><td><p>15.0 (5.6)</p><p>(p&lt;0.05)</p></td></tr><tr><td rowspan="2"><p>ENT-surgery</p></td><td rowspan="2"><p>4-11</p><p>(50)</p></td><td><p>TIVA: propofol (3 mg/kg/h) + remifentanil (0.5 &mu;g/kg/min)</p></td><td><p>11 (3.7)</p></td></tr><tr><td><p>Inhalation anaesthesia: desflurane (1.3 MAC) and N<sub>2</sub>O mixture</p></td><td><p>9.4 (2.9)</p><p>Not significant</p></td></tr><tr><td rowspan="2"><p>General or ENT surgery</p></td><td><p>2-12</p><p>(153)</p></td><td><p>TIVA: remifentanil (0.2 - 0.5&mu;g/kg/min) +</p><p>propofol (100 - 200 &mu;g/kg/min)</p></td><td rowspan="2"><p>Comparable extubation times (based on limited data)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Inhalation anaesthesia: sevoflurane (1 - 1.5 MAC) + N<sub>2</sub>O mixture</p></td></tr></tbody></table><p>In the study in lower abdominal/urological surgery comparing remifentanil/propofol with remifentanil/sevoflurane, hypotension occurred significantly more often under&nbsp;remifentanil/sevoflurane, and bradycardia occurred significantly more often under remifentanil/propofol. In the study in ENT surgery comparing remifentanil/propofol with desflurane/nitrous oxide, a significantly higher heart rate was seen in subjects receiving desflurane/nitrous oxide compared with remifentanil/propofol and with baseline values.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Following administration of the recommended doses of remifentanil, the effective biological half-life is 3-10 minutes. The average clearance of remifentanil in young healthy adults is 40 ml/min/kg, the central volume of distribution is 100 ml/kg and the steady-state volume of distribution is 350 ml/kg. In children aged 1 to 12 years, remifentanil clearance and volume of distribution decreases with increasing age; the values of these parameters in neonates are approximately twice those of healthy young adults. Blood concentrations of remifentanil are proportional to the dose administered throughout the recommended dose range. For every 0.1 micrograms/kg/min increase in infusion rate, the blood concentration of remifentanil will rise 2.5 nanograms/ml. Remifentanil is approximately 70% bound to plasma proteins.</p><p><strong>Metabolism</strong></p><p>Remifentanil is an esterase metabolised opioid that is susceptible to metabolism by non-specific blood and tissue esterases. The metabolism of remifentanil results in the formation of an essentially inactive carboxylic acid metabolite (1/4600th as potent as remifentanil). The half life of the metabolite in healthy adults is 2 hours. Approximately 95% of remifentanil is recovered in the urine as the carboxylic acid metabolite. Remifentanil is not a substrate for plasma cholinesterase.</p><p><strong>Cardiac anaesthesia</strong></p><p>The clearance of remifentanil is reduced by approximately 20% during hypothermic (28&deg;C) cardiopulmonary bypass. A decrease in body temperature lowers elimination clearance by 3% per degree centigrade.</p><p><strong>Renal impairment</strong></p><p>The rapid recovery from remifentanil-based sedation and analgesia is unaffected by renal status.</p><p>The pharmacokinetics of remifentanil are not significantly changed in patients with varying degrees of renal impairment even after administration for up to 3 days in the intensive care setting.</p><p>The clearance of the carboxylic acid metabolite is reduced in patients with renal impairment. Especially in intensive care patients with moderate/severe renal impairment, the concentration of the carboxylic acid metabolite may exceed 250-fold the level of remifentanil at steady-state in some patients. Clinical data demonstrate that the accumulation of the metabolite does not result in clinically relevant mu-opioid effects even after administration of remifentanil infusions for up to 3 days in these patients.</p><p>There is no evidence that remifentanil is extracted during renal replacement therapy.</p><p>The carboxylic acid metabolite is extracted during haemodialysis by 25 - 35 %.</p><p><strong>Hepatic impairment</strong></p><p>The pharmacokinetics of remifentanil are not changed in patients with severe hepatic impairment awaiting liver transplant, or during the anhepatic phase of liver transplant surgery. Patients with severe hepatic impairment may be slightly more sensitive to the respiratory depressant effects of remifentanil. These patients should be closely monitored and the dose of remifentanil should be titrated to the individual patient need.</p><p><strong>Paediatric patients </strong></p><p>The average clearance and steady state volume of distribution of remifentanil are increased in younger children and decline to young healthy adult values by age 17. The elimination half-life of remifentanil in neonates is not significantly different from that of young healthy adults. Changes in analgesic effect after changes in infusion rate of remifentanil should be rapid and similar to those seen in young healthy adults. The pharmacokinetics of the carboxylic acid metabolite in paediatric patients 2-17 years of age are similar to those seen in adults after correcting for differences in body weight.</p><p><strong>Elderly</strong></p><p>The clearance of remifentanil is slightly reduced (approximately 25%) in elderly patients &gt;65 years) compared to young patients. The pharmacodynamic activity of remifentanil increases with increasing age. Elderly patients have a remifentanil EC50 for formation of delta waves on the electroencephalogram (EEG) that is 50% lower than young patients; therefore, the initial dose of remifentanil should be reduced by 50% in elderly patients and then carefully titrated to meet the individual patient need.</p><p><strong>Placental and milk transfer</strong></p><p>In a human clinical trial, the mean ratio of maternal arterial to umbilical venous concentration indicated that the neonate was exposed approximately 50% concentration of remifentanil to that in the mother. The mean umbilical arterio-venous ratio of remifentanil concentrations was approximately 30% suggesting metabolism of remifentanil in the neonate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Intrathecal administration of the glycine formulation without remifentanil to dogs caused agitation, pain and hind limb dysfunction and incoordination. These effects are believed to be secondary to the glycine excipient. Glycine is a commonly used excipient in intravenous products and this finding has no relevance for intravenous administration of Ultiva.</p><p>Remifentanil, like other opioid agonists, produced increases in action potential duration (APD) in dog isolated Purkinje fibres. For remifentanil, the effects were seen at concentrations of 1 &mu;M or higher (which are higher than plasma concentrations seen in clinical practice). There were no effects at a concentration of 0.1 &mu;M.</p><p>The major metabolite remifentanil acid had no effect on APD up to the maximum tested concentration of 10 &mu;M.</p><p><strong>Reproductive toxicity studies</strong></p><p>Remifentanil has been shown to reduce fertility in male rats when administered daily by intravenous injection for at least 70 days at a dose of 0.5 mg/kg, or approximately 250 times the maximum recommended human bolus dose of 2 micrograms/kg. The fertility of female rats was not affected at doses up to 1 mg/kg when administered for at least 15 days prior to mating. No teratogenic effects have been observed with remifentanil at doses up to 5 mg/kg in rats and 0.8 mg/kg in rabbits. Administration of remifentanil to rats throughout late gestation and lactation at doses up to 5 mg/kg IV had no significant effect on the survival, development, or reproductive performance of the F1 generation.</p><p><strong>Genotoxicity </strong></p><p>Remifentanil was devoid of genotoxic activity in bacteria and in rat liver or mouse bone marrow cells in vivo. However, a positive response was seen in vitro in different mammalian cell systems in the presence of a metabolic activation system. This activity was seen only at concentrations more than three orders of magnitude higher than therapeutic blood levels.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Glycine Ph. Eur.</p><p>Hydrochloric acid Ph. Eur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ultiva should only be reconstituted and diluted with those infusion solutions recommended (see section 6.6).</p><p>It should not be reconstituted, diluted or mixed with Lactated Ringer&#39;s Injection or Lactated Ringer&#39;s and 5% Dextrose Injection.</p><p>Ultiva should not be mixed with propofol in the same infusion bag prior to administration.</p><p>Administration of Ultiva into the same intravenous line with blood/serum/plasma is not recommended. Non-specific esterases in blood products may lead to the hydrolysis of remifentanil to its inactive metabolite.</p><p>Ultiva should not be mixed with other therapeutic agents prior to administration.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ultiva for Injection 1 mg: 18 months
Ultiva for Injection 2 mg: 2 years
Ultiva for Injection 5 mg: 3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store at or below 25&deg;C.</p><p>The reconstituted solution of Ultiva is chemically and physically stable for 24 hours at room temperature (25&deg;C). However, Ultiva does not contain an antimicrobial preservative and thus care must be taken to assure the sterility of prepared solutions, reconstituted product should be used promptly, and any unused material discarded.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ultiva for Injection 1 mg for intravenous use is available as 1 mg of Remifentanil lyophilised powder in 3 ml vials, in cartons of 5.</p><p>Ultiva for Injection 2 mg for intravenous use is available as 2 mg of Remifentanil lyophilised powder in 5 ml vials, in cartons of 5.</p><p>Ultiva for Injection 5 mg for intravenous use is available as 5 mg of Remifentanil lyophilised powder in 10 ml vials, in cartons of 5.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ultiva should be prepared for intravenous use by adding, as appropriate 1, 2, or 5 ml of diluent to give a reconstituted solution with a concentration of 1 mg/ml remifentanil. The reconstituted solution is clear, colourless, and practically free from particulate material. After reconstitution, visually inspect the product (where the container permits) for particulate material, discolouration or damage of container. Discard any solution where such defects are observed. Reconstituted product is for single use only. Any unused material should be discarded.</p><p>Ultiva should not be administered by manually-controlled infusion without further dilution to concentrations of 20 to 250 micrograms/ml (50 micrograms/ml is the recommended dilution for adults and 20 to 25 micrograms/ml for paediatric patients aged 1 year and over).</p><p>Ultiva should not be administered by TCI without further dilution (20 to 50 micrograms/ml is the recommended dilution for TCI).</p><p>The dilution is dependent upon the technical capability of the infusion device and the anticipated requirements of the patient.</p><p>One of the following IV fluids listed below should be used for dilution:</p><p>Water for Injections</p><p>Glucose 5% solution for injection</p><p>Glucose 5% and Sodium Chloride 0.9% solution for injection</p><p>Sodium Chloride 0.9% solution for injection</p><p>Sodium Chloride 0.45% solution for injection</p><p>After dilution, visually inspect the product to ensure it is clear, colourless, practically free from particulate matter and the container is undamaged. Discard any solution where such defects are observed.</p><p>Ultiva has been shown to be compatible with the following intravenous fluids when administered into a running IV catheter:</p><p>Lactated Ringer&#39;s solution for injection</p><p>Lactated Ringer&#39;s and Glucose 5% solution for injection</p><p>Ultiva has been shown to be compatible with propofol when administered into a running IV catheter.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>The following tables give guidelines for infusion rates of Ultiva for manually-controlled infusion:</p><p><strong>Table 1. Ultiva for Injection Infusion Rates (ml/kg/h)</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p><strong>Drug Delivery Rate (micrograms/kg/min)</strong></p></td><td colspan="4"><p><strong>Infusion Delivery Rate (ml/kg/h) for Solution Concentrations of</strong></p></td></tr><tr><td><p><strong>20</strong></p><p><strong>micrograms/ml 1 mg/50 ml</strong></p></td><td><p><strong>25</strong></p><p><strong>micrograms/ml 1 mg/40 ml</strong></p></td><td><p><strong>50</strong></p><p><strong>micrograms/ml 1 mg/20 ml</strong></p></td><td><p><strong>250</strong></p><p><strong>micrograms/ml 10 mg/40 ml</strong></p></td></tr><tr><td><p>0.0125</p></td><td><p>0.038</p></td><td><p>0.03</p></td><td><p>0.015</p></td><td><p>Not recommended</p></td></tr><tr><td><p>0.025</p></td><td><p>0.075</p></td><td><p>0.06</p></td><td><p>0.03</p></td><td><p>Not recommended</p></td></tr><tr><td><p>0.05</p></td><td><p>0.15</p></td><td><p>0.12</p></td><td><p>0.06</p></td><td><p>0.012</p></td></tr><tr><td><p>0.075</p></td><td><p>0.23</p></td><td><p>0.18</p></td><td><p>0.09</p></td><td><p>0.018</p></td></tr><tr><td><p>0.1</p></td><td><p>0.3</p></td><td><p>0.24</p></td><td><p>0.12</p></td><td><p>0.024</p></td></tr><tr><td><p>0.15</p></td><td><p>0.45</p></td><td><p>0.36</p></td><td><p>0.18</p></td><td><p>0.036</p></td></tr><tr><td><p>0.2</p></td><td><p>0.6</p></td><td><p>0.48</p></td><td><p>0.24</p></td><td><p>0.048</p></td></tr><tr><td><p>0.25</p></td><td><p>0.75</p></td><td><p>0.6</p></td><td><p>0.3</p></td><td><p>0.06</p></td></tr><tr><td><p>0.5</p></td><td><p>1.5</p></td><td><p>1.2</p></td><td><p>0.6</p></td><td><p>0.12</p></td></tr><tr><td><p>0.75</p></td><td><p>2.25</p></td><td><p>1.8</p></td><td><p>0.9</p></td><td><p>0.18</p></td></tr><tr><td><p>1.0</p></td><td><p>3.0</p></td><td><p>2.4</p></td><td><p>1.2</p></td><td><p>0.24</p></td></tr><tr><td><p>1.25</p></td><td><p>3.75</p></td><td><p>3.0</p></td><td><p>1.5</p></td><td><p>0.3</p></td></tr><tr><td><p>1.5</p></td><td><p>4.5</p></td><td><p>3.6</p></td><td><p>1.8</p></td><td><p>0.36</p></td></tr><tr><td><p>1.75</p></td><td><p>5.25</p></td><td><p>4.2</p></td><td><p>2.1</p></td><td><p>0.42</p></td></tr><tr><td><p>2.0</p></td><td><p>6.0</p></td><td><p>4.8</p></td><td><p>2.4</p></td><td><p>0.48</p></td></tr></tbody></table><p><strong>Table 2. Ultiva for Injection Infusion Rates (ml/h) for a 20 micrograms/ml Solution</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p><strong>Infusion Rate(micrograms/kg/min)</strong></p></td><td colspan="7"><p><strong>Patient Weight (kg)</strong></p></td></tr><tr><td><p><strong>5</strong></p></td><td><p><strong>10</strong></p></td><td><p><strong>20</strong></p></td><td><p><strong>30</strong></p></td><td><p><strong>40</strong></p></td><td><p><strong>50</strong></p></td><td><p><strong>60</strong></p></td></tr><tr><td><p>0.0125</p></td><td><p>0.188</p></td><td><p>0.375</p></td><td><p>0.75</p></td><td><p>1.125</p></td><td><p>1.5</p></td><td><p>1.875</p></td><td><p>2.25</p></td></tr><tr><td><p>0.025</p></td><td><p>0.375</p></td><td><p>0.75</p></td><td><p>1.5</p></td><td><p>2.25</p></td><td><p>3.0</p></td><td><p>3.75</p></td><td><p>4.5</p></td></tr><tr><td><p>0.05</p></td><td><p>0.75</p></td><td><p>1.5</p></td><td><p>3.0</p></td><td><p>4.5</p></td><td><p>6.0</p></td><td><p>7.5</p></td><td><p>9.0</p></td></tr><tr><td><p>0.075</p></td><td><p>1.125</p></td><td><p>2.25</p></td><td><p>4.5</p></td><td><p>6.75</p></td><td><p>9.0</p></td><td><p>11.25</p></td><td><p>13.5</p></td></tr><tr><td><p>0.1</p></td><td><p>1.5</p></td><td><p>3.0</p></td><td><p>6.0</p></td><td><p>9.0</p></td><td><p>12.0</p></td><td><p>15.0</p></td><td><p>18.0</p></td></tr><tr><td><p>0.15</p></td><td><p>2.25</p></td><td><p>4.5</p></td><td><p>9.0</p></td><td><p>13.5</p></td><td><p>18.0</p></td><td><p>22.5</p></td><td><p>27.0</p></td></tr><tr><td><p>0.2</p></td><td><p>3.0</p></td><td><p>6.0</p></td><td><p>12.0</p></td><td><p>18.0</p></td><td><p>24.0</p></td><td><p>30.0</p></td><td><p>36.0</p></td></tr><tr><td><p>0.25</p></td><td><p>3.75</p></td><td><p>7.5</p></td><td><p>15.0</p></td><td><p>22.5</p></td><td><p>30.0</p></td><td><p>37.5</p></td><td><p>45.0</p></td></tr><tr><td><p>0.3</p></td><td><p>4.5</p></td><td><p>9.0</p></td><td><p>18.0</p></td><td><p>27.0</p></td><td><p>36.0</p></td><td><p>45.0</p></td><td><p>54.0</p></td></tr><tr><td><p>0.35</p></td><td><p>5.25</p></td><td><p>10.5</p></td><td><p>21.0</p></td><td><p>31.5</p></td><td><p>42.0</p></td><td><p>52.5</p></td><td><p>63.0</p></td></tr><tr><td><p>0.4</p></td><td><p>6.0</p></td><td><p>12.0</p></td><td><p>24.0</p></td><td><p>36.0</p></td><td><p>48.0</p></td><td><p>60.0</p></td><td><p>72.0</p></td></tr></tbody></table><p><strong>Table 3. Ultiva for Injection Infusion Rates (ml/h) for a 25 micrograms/ml Solution</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p><strong>Infusion Rate (micrograms/kg/min)</strong></p></td><td colspan="10"><p><strong>Patient Weight (kg)</strong></p></td></tr><tr><td><p><strong>10</strong></p></td><td><p><strong>20</strong></p></td><td><p><strong>30</strong></p></td><td><p><strong>40</strong></p></td><td><p><strong>50</strong></p></td><td><p><strong>60</strong></p></td><td><p><strong>70</strong></p></td><td><p><strong>80</strong></p></td><td><p><strong>90</strong></p></td><td><p><strong>100</strong></p></td></tr><tr><td><p>0.0125</p></td><td><p>0.3</p></td><td><p>0.6</p></td><td><p>0.9</p></td><td><p>1.2</p></td><td><p>1.5</p></td><td><p>1.8</p></td><td><p>2.1</p></td><td><p>2.4</p></td><td><p>2.7</p></td><td><p>3.0</p></td></tr><tr><td><p>0.025</p></td><td><p>0.6</p></td><td><p>1.2</p></td><td><p>1.8</p></td><td><p>2.4</p></td><td><p>3.0</p></td><td><p>3.6</p></td><td><p>4.2</p></td><td><p>4.8</p></td><td><p>5.4</p></td><td><p>6.0</p></td></tr><tr><td><p>0.05</p></td><td><p>1.2</p></td><td><p>2.4</p></td><td><p>3.6</p></td><td><p>4.8</p></td><td><p>6.0</p></td><td><p>7.2</p></td><td><p>8.4</p></td><td><p>9.6</p></td><td><p>10.8</p></td><td><p>12.0</p></td></tr><tr><td><p>0.075</p></td><td><p>1.8</p></td><td><p>3.6</p></td><td><p>5.4</p></td><td><p>7.2</p></td><td><p>9.0</p></td><td><p>10.8</p></td><td><p>12.6</p></td><td><p>14.4</p></td><td><p>16.2</p></td><td><p>18.0</p></td></tr><tr><td><p>0.1</p></td><td><p>2.4</p></td><td><p>4.8</p></td><td><p>7.2</p></td><td><p>9.6</p></td><td><p>12.0</p></td><td><p>14.4</p></td><td><p>16.8</p></td><td><p>19.2</p></td><td><p>21.6</p></td><td><p>24.0</p></td></tr><tr><td><p>0.15</p></td><td><p>3.6</p></td><td><p>7.2</p></td><td><p>10.8</p></td><td><p>14.4</p></td><td><p>18.0</p></td><td><p>21.6</p></td><td><p>25.2</p></td><td><p>28.8</p></td><td><p>32.4</p></td><td><p>36.0</p></td></tr><tr><td><p>0.2</p></td><td><p>4.8</p></td><td><p>9.6</p></td><td><p>14.4</p></td><td><p>19.2</p></td><td><p>24.0</p></td><td><p>28.8</p></td><td><p>33.6</p></td><td><p>38.4</p></td><td><p>43.2</p></td><td><p>48.0</p></td></tr></tbody></table><p><strong>Table 4. Ultiva for Injection Infusion Rates (ml/h) for a 50 micrograms/ml Solution</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p><strong>Infusion Rate (micrograms/kg/min)</strong></p></td><td colspan="8"><p><strong>Patient Weight (kg)</strong></p></td></tr><tr><td><p><strong>30</strong></p></td><td><p><strong>40</strong></p></td><td><p><strong>50</strong></p></td><td><p><strong>60</strong></p></td><td><p><strong>70</strong></p></td><td><p><strong>80</strong></p></td><td><p><strong>90</strong></p></td><td><p><strong>100</strong></p></td></tr><tr><td><p>0.025</p></td><td><p>0.9</p></td><td><p>1.2</p></td><td><p>1.5</p></td><td><p>1.8</p></td><td><p>2.1</p></td><td><p>2.4</p></td><td><p>2.7</p></td><td><p>3.0</p></td></tr><tr><td><p>0.05</p></td><td><p>1.8</p></td><td><p>2.4</p></td><td><p>3.0</p></td><td><p>3.6</p></td><td><p>4.2</p></td><td><p>4.8</p></td><td><p>5.4</p></td><td><p>6.0</p></td></tr><tr><td><p>0.075</p></td><td><p>2.7</p></td><td><p>3.6</p></td><td><p>4.5</p></td><td><p>5.4</p></td><td><p>6.3</p></td><td><p>7.2</p></td><td><p>8.1</p></td><td><p>9.0</p></td></tr><tr><td><p>0.1</p></td><td><p>3.6</p></td><td><p>4.8</p></td><td><p>6.0</p></td><td><p>7.2</p></td><td><p>8.4</p></td><td><p>9.6</p></td><td><p>10.8</p></td><td><p>12.0</p></td></tr><tr><td><p>0.15</p></td><td><p>5.4</p></td><td><p>7.2</p></td><td><p>9.0</p></td><td><p>10.8</p></td><td><p>12.6</p></td><td><p>14.4</p></td><td><p>16.2</p></td><td><p>18.0</p></td></tr><tr><td><p>0.2</p></td><td><p>7.2</p></td><td><p>9.6</p></td><td><p>12.0</p></td><td><p>14.4</p></td><td><p>16.8</p></td><td><p>19.2</p></td><td><p>21.6</p></td><td><p>24.0</p></td></tr><tr><td><p>0.25</p></td><td><p>9.0</p></td><td><p>12.0</p></td><td><p>15.0</p></td><td><p>18.0</p></td><td><p>21.0</p></td><td><p>24.0</p></td><td><p>27.0</p></td><td><p>30.0</p></td></tr><tr><td><p>0.5</p></td><td><p>18.0</p></td><td><p>24.0</p></td><td><p>30.0</p></td><td><p>36.0</p></td><td><p>42.0</p></td><td><p>48.0</p></td><td><p>54.0</p></td><td><p>60.0</p></td></tr><tr><td><p>0.75</p></td><td><p>27.0</p></td><td><p>36.0</p></td><td><p>45.0</p></td><td><p>54.0</p></td><td><p>63.0</p></td><td><p>72.0</p></td><td><p>81.0</p></td><td><p>90.0</p></td></tr><tr><td><p>1.0</p></td><td><p>36.0</p></td><td><p>48.0</p></td><td><p>60.0</p></td><td><p>72.0</p></td><td><p>84.0</p></td><td><p>96.0</p></td><td><p>108.0</p></td><td><p>120.0</p></td></tr><tr><td><p>1.25</p></td><td><p>45.0</p></td><td><p>60.0</p></td><td><p>75.0</p></td><td><p>90.0</p></td><td><p>105.0</p></td><td><p>120.0</p></td><td><p>135.0</p></td><td><p>150.0</p></td></tr><tr><td><p>1.5</p></td><td><p>54.0</p></td><td><p>72.0</p></td><td><p>90.0</p></td><td><p>108.0</p></td><td><p>126.0</p></td><td><p>144.0</p></td><td><p>162.0</p></td><td><p>180.0</p></td></tr><tr><td><p>1.75</p></td><td><p>63.0</p></td><td><p>84.0</p></td><td><p>105.0</p></td><td><p>126.0</p></td><td><p>147.0</p></td><td><p>168.0</p></td><td><p>189.0</p></td><td><p>210.0</p></td></tr><tr><td><p>2.0</p></td><td><p>72.0</p></td><td><p>96.0</p></td><td><p>120.0</p></td><td><p>144.0</p></td><td><p>168.0</p></td><td><p>192.0</p></td><td><p>216.0</p></td><td><p>240.0</p></td></tr></tbody></table><p><strong>Table 5. Ultiva for Injection Infusion Rates (ml/h) for a 250 micrograms/ml Solution</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p><strong>Infusion Rate (micrograms/kg/min)</strong></p></td><td colspan="8"><p><strong>Patient Weight (kg)</strong></p></td></tr><tr><td><p><strong>30</strong></p></td><td><p><strong>40</strong></p></td><td><p><strong>50</strong></p></td><td><p><strong>60</strong></p></td><td><p><strong>70</strong></p></td><td><p><strong>80</strong></p></td><td><p><strong>90</strong></p></td><td><p><strong>100</strong></p></td></tr><tr><td><p>0.1</p></td><td><p>0.72</p></td><td><p>0.96</p></td><td><p>1.20</p></td><td><p>1.44</p></td><td><p>1.68</p></td><td><p>1.92</p></td><td><p>2.16</p></td><td><p>2.40</p></td></tr><tr><td><p>0.15</p></td><td><p>1.08</p></td><td><p>1.44</p></td><td><p>1.80</p></td><td><p>2.16</p></td><td><p>2.52</p></td><td><p>2.88</p></td><td><p>3.24</p></td><td><p>3.60</p></td></tr><tr><td><p>0.2</p></td><td><p>1.44</p></td><td><p>1.92</p></td><td><p>2.40</p></td><td><p>2.88</p></td><td><p>3.36</p></td><td><p>3.84</p></td><td><p>4.32</p></td><td><p>4.80</p></td></tr><tr><td><p>0.25</p></td><td><p>1.80</p></td><td><p>2.40</p></td><td><p>3.00</p></td><td><p>3.60</p></td><td><p>4.20</p></td><td><p>4.80</p></td><td><p>5.40</p></td><td><p>6.00</p></td></tr><tr><td><p>0.5</p></td><td><p>3.60</p></td><td><p>4.80</p></td><td><p>6.00</p></td><td><p>7.20</p></td><td><p>8.40</p></td><td><p>9.60</p></td><td><p>10.80</p></td><td><p>12.00</p></td></tr><tr><td><p>0.75</p></td><td><p>5.40</p></td><td><p>7.20</p></td><td><p>9.00</p></td><td><p>10.80</p></td><td><p>12.60</p></td><td><p>14.40</p></td><td><p>16.20</p></td><td><p>18.00</p></td></tr><tr><td><p>1.0</p></td><td><p>7.20</p></td><td><p>9.60</p></td><td><p>12.00</p></td><td><p>14.40</p></td><td><p>16.80</p></td><td><p>19.20</p></td><td><p>21.60</p></td><td><p>24.00</p></td></tr><tr><td><p>1.25</p></td><td><p>9.00</p></td><td><p>12.00</p></td><td><p>15.00</p></td><td><p>18.00</p></td><td><p>21.00</p></td><td><p>24.00</p></td><td><p>27.00</p></td><td><p>30.00</p></td></tr><tr><td><p>1.5</p></td><td><p>10.80</p></td><td><p>14.40</p></td><td><p>18.00</p></td><td><p>21.60</p></td><td><p>25.20</p></td><td><p>28.80</p></td><td><p>32.40</p></td><td><p>36.00</p></td></tr><tr><td><p>1.75</p></td><td><p>12.60</p></td><td><p>16.80</p></td><td><p>21.00</p></td><td><p>25.20</p></td><td><p>29.40</p></td><td><p>33.60</p></td><td><p>37.80</p></td><td><p>42.00</p></td></tr><tr><td><p>2.0</p></td><td><p>14.40</p></td><td><p>19.20</p></td><td><p>24.00</p></td><td><p>28.80</p></td><td><p>33.60</p></td><td><p>38.40</p></td><td><p>43.20</p></td><td><p>48.00</p></td></tr></tbody></table><p>The following table provides the equivalent blood remifentanil concentration using a TCI approach for various manually-controlled infusion rates at steady state:</p><p><strong>Table 6. Remifentanil Blood Concentrations (nanograms/ml) estimated using the Minto (1997) Pharmacokinetic Model in a 70 kg, 170 cm, 40 Year Old Male Patient for Various Manually-Controlled Infusion rates (micrograms/kg/min) at Steady State.</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Ultiva Infusion Rate (micrograms/kg/min)</strong></p></td><td><p><strong>Remifentanil Blood Concentration (nanograms/ml)</strong></p></td></tr><tr><td><p>0.05</p></td><td><p>1.3</p></td></tr><tr><td><p>0.10</p></td><td><p>2.6</p></td></tr><tr><td><p>0.25</p></td><td><p>6.3</p></td></tr><tr><td><p>0.40</p></td><td><p>10.4</p></td></tr><tr><td><p>0.50</p></td><td><p>12.6</p></td></tr><tr><td><p>1.0</p></td><td><p>25.2</p></td></tr><tr><td><p>2.0</p></td><td><p>50.5</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Aspen Pharma Trading Limited, 
3016 Lake Drive, 
City West Business Campus,
Dublin 24,
 Ireland
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                March/ 2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>